15 Sep 2023 08:58
PRESS RELEASE
Correction - Change of Interim Results Date
The following announcement replaces the notification released on 15 September 2023 at 07.00 a.m. under RNS number 5253M.
The original RNS incorrectly stated that Ergomed will announce its interim results for the six months ended 30 June 2023, on 26 September 2023. This has been corrected to Friday, 22 September 2023.
The full amended text is shown below.
Guildford, UK - 15 September 2023: Ergomed plc, (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, announces that it will now release its interim results for the six months ended 30 June 2023 on Friday 22 September 2023.
ENDS
Enquiries:
Ergomed plc | Tel: +44 (0) 1483 402 975 |
Miroslav Reljanović (Executive Chairman) | |
Jonathan Curtain (Chief Financial Officer) Keith Byrne (Senior Vice President, Capital Markets and Strategy) | |
Numis (Nominated Adviser and Joint Broker) | Tel: +44 (0) 20 7260 1000 |
Freddie Barnfield / Euan Brown / Jack McLaren | |
Peel Hunt (Joint Broker) James Steel / Dr Christopher Golden |
Tel: +44 (0) 20 7418 8900
|
ICR Consilium - for UK enquiries | Tel: +44 (0) 20 3709 5700 |
Chris Gardner / Matthew Neal | ergomed@consilium-comms.com |
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO) and mission-critical regulatory compliance and consulting services under the ADAMAS brand. For further information, visit: http://ergomedplc.com.